arrow_back Back to App

$10 Billion Research Boost for Long COVID Treatment and Drug Price Control.

This act allocates $10 billion over ten years to dramatically accelerate research into Long COVID and related chronic conditions, aiming to quickly identify new prevention and treatment methods. A major consequence for citizens is the establishment of price controls, ensuring that any resulting drugs or devices are affordable for the public and priced fairly compared to major international markets.
Key points
Establishes a $1 billion annual research program at NIH dedicated to finding the causes, treatments, and prevention methods for Long COVID in adults and children.
Implements price caps on new drugs and devices developed using federal funds, ensuring they are reasonably priced and do not exceed the lowest price charged in six major developed countries.
Funds specialized, multidisciplinary clinics, provider education programs, and public information campaigns to improve access to coordinated care.
Strengthens public health surveillance (CDC) of Long COVID and similar chronic conditions to better understand the disease burden and severity.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_4964
Sponsor: Sen. Sanders, Bernard [I-VT]
Process start date: 2024-08-01
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Long COVID Research Moonshot Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_4964.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-08-01.

What are the main provisions?

Key points include:

  • Establishes a $1 billion annual research program at NIH dedicated to finding the causes, treatments, and prevention methods for Long COVID in adults and children.
  • Implements price caps on new drugs and devices developed using federal funds, ensuring they are reasonably priced and do not exceed the lowest price charged in six major developed countries.
  • Funds specialized, multidisciplinary clinics, provider education programs, and public information campaigns to improve access to coordinated care.
  • Strengthens public health surveillance (CDC) of Long COVID and similar chronic conditions to better understand the disease burden and severity.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Sanders, Bernard [I-VT].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

CATEGORIES

Health Public Investments